Ibogaine vs Psilocybin
Comparing two of nature's most powerful psychedelic medicines for addiction and mental health
Two Plant Medicines, Different Strengths
Ibogaine (from the African Tabernanthe iboga plant) and psilocybin (from Psilocybe mushrooms) are both naturally occurring psychedelics with remarkable therapeutic potential. However, they work through fundamentally different mechanisms and excel at treating different conditions. Ibogaine is the most powerful known addiction interrupter; psilocybin is emerging as a breakthrough treatment for depression and end-of-life anxiety.
Quick Comparison
| Feature | Ibogaine | Psilocybin |
|---|---|---|
| Source | Iboga root bark (Tabernanthe iboga) | Psilocybe mushrooms (200+ species) |
| Primary Use | Opioid & stimulant addiction | Depression, anxiety, end-of-life distress |
| Mechanism | Multi-receptor reset (NMDA, opioid, serotonin, GDNF) | 5-HT2A agonist (serotonin), default mode network disruption |
| Duration | 24-48 hours (active metabolite weeks-months) | 4-6 hours (effects fade same day) |
| Sessions | 1 flood dose, optional boosters | 1-3 sessions spaced weeks apart |
| Experience | Analytical, visionary, life review | Emotional, mystical, ego dissolution |
| Withdrawal Effect | Eliminates opioid withdrawal | No direct effect on physical withdrawal |
| Physical Safety | Cardiac risks (QT prolongation) | Extremely safe physically |
| Legal Status (US) | Schedule I, no decrim | Schedule I federally; legal in OR, decrim in CO + cities |
| Cost | $5,000-$15,000 (+ travel) | $1,500-$3,500 per session |
| FDA Progress | Early clinical trials | Breakthrough Therapy designation; Phase III trials |
How They Work: Different Mechanisms
Ibogaine: The Addiction Interrupter
Ibogaine is pharmacologically unique, acting on multiple receptor systems simultaneously:
- Opioid receptor reset: Modulates mu, kappa, and delta receptors, returning them to a pre-addicted state and eliminating physical dependence
- NMDA antagonism: Blocks glutamate excitotoxicity, similar to ketamine's mechanism
- 5-HT2A agonism: Produces psychedelic effects (shared with psilocybin) for psychological processing
- GDNF upregulation: Glial cell line-derived neurotrophic factor promotes neuronal repair and sustained craving reduction
- Noribogaine: Long-acting metabolite provides anti-depressant and anti-craving effects for weeks to months
Psilocybin: The Consciousness Expander
Psilocybin (converted to psilocin in the body) works primarily through serotonin pathways:
- 5-HT2A agonism: Primary mechanism. Activates serotonin 2A receptors, producing classic psychedelic effects
- Default mode network disruption: Temporarily dissolves the brain's "autopilot" network, breaking rigid thought patterns and rumination loops
- Neuroplasticity: Promotes dendritic spine growth and new neural connections within hours (Shao et al., 2021)
- Amygdala modulation: Reduces fear response, enabling emotional processing of traumatic memories
- Connectome reorganization: Creates novel connections between brain regions that don't normally communicate, enabling fresh perspectives
Key Difference: Physical vs Psychological
Ibogaine works on both the physical (receptor reset, withdrawal elimination) and psychological levels. Psilocybin works almost entirely at the psychological level—changing thought patterns, emotional processing, and perspective—without directly affecting physical dependence. This is why ibogaine is the treatment of choice for opioid addiction, while psilocybin excels at depression and existential distress.
Effectiveness by Condition
Opioid Addiction
- Ibogaine: Highly effective. 80-95% withdrawal elimination. 50-65% sustained abstinence at 12 months with aftercare (Brown & Alper, 2018; Noller et al., 2018)
- Psilocybin: Not effective for physical opioid withdrawal. May provide psychological motivation for recovery but cannot address physical dependence
Depression
- Ibogaine: Promising. Noribogaine has antidepressant properties. Some patients report significant mood improvement. Limited formal research
- Psilocybin: Strong evidence. FDA Breakthrough Therapy designation. COMPASS Pathways and Usona Institute Phase III trials show 60-70% response rate in treatment-resistant depression (Carhart-Harris et al., 2021; Goodwin et al., 2022)
End-of-Life Anxiety
- Ibogaine: Limited research. Some anecdotal reports of existential peace post-treatment
- Psilocybin: Exceptional evidence. NYU and Johns Hopkins studies show 80%+ sustained reduction in anxiety and depression in terminal patients. Often described as the most meaningful experience of participants' lives (Griffiths et al., 2016)
Tobacco & Alcohol Addiction
- Ibogaine: Effective for alcohol through craving reduction and psychological processing. Less studied for tobacco specifically
- Psilocybin: Johns Hopkins pilot study showed 80% tobacco abstinence at 6 months—far exceeding any other treatment (Johnson et al., 2014). Promising results for alcohol use disorder
PTSD & Trauma
- Ibogaine: Strong for trauma co-occurring with addiction. Veterans report significant PTSD reduction. Formal trials underway
- Psilocybin: Growing evidence for PTSD, especially when combined with psychotherapy. Smaller effect than MDMA for PTSD specifically, but promising
The Treatment Experience
Ibogaine Journey (24-48 Hours)
The ibogaine experience is one of the most intense and lengthy of any psychedelic:
- Hours 1-4 (Onset): Buzzing sensation, visual patterns, increasing introspection
- Hours 4-12 (Visionary Phase): Vivid "life review" visions, childhood memories, confrontation with patterns and behaviors, often described as watching a movie of your life
- Hours 12-24 (Cognitive Phase): Deep analytical processing, emotional insights, reduced visuals but intense reflection
- Days 2-7 (Recovery): Physical fatigue, emotional sensitivity, insomnia common, temporary ataxia
- Character: Often described as stern, analytical, and confrontational. "The teacher that tells you what you need to hear, not what you want to hear"
Psilocybin Journey (4-6 Hours)
The psilocybin experience is shorter but can be equally profound:
- Minutes 20-60 (Onset): Body sensations, shifting perceptions, emotional warmth or anxiety
- Hours 1-3 (Peak): Vivid visual imagery, ego dissolution, mystical unity experiences, deep emotional release, time distortion
- Hours 3-5 (Plateau): Insights solidify, emotional processing continues, return of ego boundaries
- Hours 5-6 (Resolution): Gradual return to baseline, often with lingering sense of awe and gratitude
- Character: Often described as warm, nurturing, and emotionally expansive. "Like being held by the universe." Can also be challenging and confrontational at higher doses
Safety Comparison
Ibogaine Safety Concerns
- Cardiac: QT prolongation is the primary risk. Requires thorough cardiac screening (EKG, electrolytes, echocardiogram)
- Drug interactions: Extensive and dangerous. Check medication safety before considering treatment
- Physical demands: The 24-48 hour duration is physically taxing. Ataxia, nausea, and fatigue are common
- Medical supervision: Continuous cardiac monitoring required in a clinical setting
- Contraindications: Heart disease, seizure disorders, severe liver/kidney disease, many medications
Psilocybin Safety Profile
- Physical safety: Exceptionally safe. No known lethal dose. Minimal cardiovascular effects. No organ toxicity
- Psychological risk: Can trigger anxiety, panic, or psychotic episodes in predisposed individuals. Proper screening and setting mitigate risk
- Drug interactions: Fewer than ibogaine. Main concerns: SSRIs (reduced effect), lithium (seizure risk), MAOIs (potentiation)
- Challenging experiences: "Bad trips" can occur but are often therapeutically productive when properly supported
- No addiction potential: Psilocybin builds rapid tolerance, making abuse difficult. No physical dependence
Legal Status & Access
Ibogaine Access
- US: Schedule I, no legal access. No state decriminalization efforts currently
- Mexico: Unregulated. Most Americans travel to clinics in Mexico
- Canada: Unscheduled. Growing number of clinics operating legally
- New Zealand: Only country where ibogaine is a legal prescribed medicine
- FDA pathway: Early-stage clinical trials. Still years from potential approval
Psilocybin Access
- Oregon: Legal supervised therapy since January 2023 (Measure 109). Licensed service centers operating
- Colorado: Decriminalized. Natural Medicine Health Act (Prop 122) establishing regulated access
- Cities: Decriminalized in Denver, Oakland, Santa Cruz, Ann Arbor, Washington DC, and others
- FDA pathway: Breakthrough Therapy designation for depression. Phase III trials ongoing. Approval possible by 2026-2027
- Clinical trials: Multiple trials actively enrolling participants at Johns Hopkins, NYU, UCSF, and other institutions
Who Should Choose Which?
Choose Ibogaine If You:
- Have opioid, stimulant, or severe alcohol addiction as your primary issue
- Need physical withdrawal elimination (not just psychological support)
- Want comprehensive neurochemical and psychological reset in one session
- Have good cardiac health (confirmed by EKG and cardiac screening)
- Are willing to travel internationally for treatment
- Have failed conventional rehab programs
Choose Psilocybin If You:
- Struggle with depression, anxiety, or end-of-life distress as primary concerns
- Want to quit tobacco or reduce alcohol use through psychological insight
- Prefer shorter sessions (4-6 hours vs 24-48 hours)
- Want treatment available in the US (Oregon, clinical trials)
- Have cardiac conditions that make ibogaine too risky
- Seek ongoing personal growth and therapeutic maintenance sessions
- Want a treatment approaching FDA approval with growing insurance prospects
Frequently Asked Questions
Is ibogaine or psilocybin better for addiction treatment?
Ibogaine is significantly more effective for physical addiction, particularly opioids. It eliminates withdrawal symptoms within hours and resets opioid receptors. Psilocybin shows promise for tobacco and alcohol cessation through psychological insight rather than neurochemical reset. For opioid addiction specifically, ibogaine is the clear choice. For behavioral addictions or alcohol, both show promise through different mechanisms.
Can you take psilocybin and ibogaine together?
No. Ibogaine and psilocybin should never be taken simultaneously due to overlapping serotonergic activity and potential cardiovascular interactions. If considering both, they should be spaced at least 4-6 weeks apart. Many practitioners recommend ibogaine first for addiction interruption, followed by psilocybin sessions months later for ongoing psychological growth and maintenance.
Which is safer, ibogaine or psilocybin?
Psilocybin has a significantly safer physical profile. It has no known lethal dose, minimal cardiovascular effects, and no organ toxicity. Ibogaine carries cardiac risks including QT prolongation and requires thorough medical screening. However, ibogaine's single-session approach means less total exposure than multiple psilocybin sessions. Both require proper set, setting, and supervision.
Is psilocybin legal in the US?
Psilocybin is a Schedule I substance federally but has been decriminalized or legalized in several jurisdictions. Oregon legalized supervised psilocybin therapy (Measure 109) effective 2023, and Colorado decriminalized and is developing regulated access. Several cities have deprioritized enforcement. Ibogaine remains Schedule I with no current US decriminalization efforts, requiring international travel for treatment.
How do the experiences compare?
Ibogaine produces a 24-48 hour journey with vivid life-review visions, deep introspection, and often a comprehensive processing of past trauma. It's intense and physically demanding. Psilocybin lasts 4-6 hours with visual imagery, emotional openness, ego dissolution, and mystical experiences. Psilocybin is generally described as warmer and more emotionally connective, while ibogaine is more analytical and confrontational.
How much does psilocybin therapy cost compared to ibogaine?
Psilocybin-assisted therapy in Oregon costs $1,500-$3,500 per session, with protocols typically involving 1-3 sessions. Total cost: $1,500-$10,500. Ibogaine treatment costs $5,000-$15,000 for a single comprehensive treatment plus travel expenses. Clinical psilocybin trials (when available) may offer free treatment. Neither is covered by insurance, though psilocybin may gain coverage as it progresses toward FDA approval.
The Bottom Line
Ibogaine and psilocybin represent different branches of the psychedelic medicine revolution. Ibogaine is unmatched for interrupting physical addiction—particularly opioids—through its multi-receptor neurochemical reset. Psilocybin is emerging as a breakthrough treatment for depression, anxiety, and behavioral addictions through profound psychological and spiritual experiences. Neither is a replacement for the other; they serve complementary roles in the expanding toolkit of psychedelic-assisted therapy.
Interested in ibogaine treatment for addiction? Contact us for a free consultation or start with our pre-screening assessment.